These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31028540)

  • 1. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
    Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
    Kast RE; Karpel-Massler G; Halatsch ME
    Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
    Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
    Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
    Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S
    Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.
    Lee JE; Lim JH; Hong YK; Yang SH
    Cancer Res Treat; 2018 Oct; 50(4):1331-1342. PubMed ID: 29334602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
    Kitabayashi T; Dong Y; Furuta T; Sabit H; Jiapaer S; Zhang J; Zhang G; Hayashi Y; Kobayashi M; Domoto T; Minamoto T; Hirao A; Nakada M
    Sci Rep; 2019 Jul; 9(1):10049. PubMed ID: 31296906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
    Guerriero C; Matera C; Del Bufalo D; De Amici M; Conti L; Dallanoce C; Tata AM
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.
    Esaki S; Nigim F; Moon E; Luk S; Kiyokawa J; Curry W; Cahill DP; Chi AS; Iafrate AJ; Martuza RL; Rabkin SD; Wakimoto H
    Int J Cancer; 2017 Dec; 141(11):2348-2358. PubMed ID: 28801914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells.
    Hothi P; Martins TJ; Chen L; Deleyrolle L; Yoon JG; Reynolds B; Foltz G
    Oncotarget; 2012 Oct; 3(10):1124-36. PubMed ID: 23165409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
    Yin J; Ge X; Shi Z; Yu C; Lu C; Wei Y; Zeng A; Wang X; Yan W; Zhang J; You Y
    Theranostics; 2021; 11(4):1763-1779. PubMed ID: 33408780
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
    Guo G; Gong K; Puliyappadamba VT; Panchani N; Pan E; Mukherjee B; Damanwalla Z; Bharia S; Hatanpaa KJ; Gerber DE; Mickey BE; Patel TR; Sarkaria JN; Zhao D; Burma S; Habib AA
    Neuro Oncol; 2019 Dec; 21(12):1529-1539. PubMed ID: 31363754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
    Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
    Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.
    Skaga E; Kulesskiy E; Fayzullin A; Sandberg CJ; Potdar S; Kyttälä A; Langmoen IA; Laakso A; Gaál-Paavola E; Perola M; Wennerberg K; Vik-Mo EO
    BMC Cancer; 2019 Jun; 19(1):628. PubMed ID: 31238897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
    Yang TC; Liu SJ; Lo WL; Chen SM; Tang YL; Tseng YY
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
    Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
    Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.